Trio Clinical Research Relocates Headquarters to Accommodate Growth
July 8, 2009, Raleigh, NC –
Trio Clinical Research, a leading clinical research services company supporting the pharmaceutical, biotechnology and medical device industry announced today a relocation of the company’s headquarters. The relocation provides Trio with larger office space to accommodate the company’s growth, and more amenable facilities for staff and visiting customers.
Trio’s new headquarters office, with 14,000 square feet of space, is located at 8045 Arco Corporate Drive, Suite 200, Raleigh, North Carolina 27617. The new office is conveniently located in Brier Creek Corporate Center and is within five miles of Raleigh-Durham International airport.
“We are thrilled with the relocation of our headquarters office to a larger and more modern facility. This move is just one of several important initiatives positioning Trio as a comprehensive provider of clinical research services. Our new facility offers us an additional 3,000 square feet, affording not only additional office space for new employees, but also more upscale conference space for hosting client meetings,” said Betsy Brown, Chief Operating Officer of Trio Clinical Research.
Trio will be hosting an Open House reception for customers, contractors and local business leaders. Details of the event will be announced in the coming days.
About Trio Clinical Research
Trio Clinical Research is an innovative clinical research services company supporting the pharmaceutical, biotechnology and medical device industries in their quest to bring novel products to the market. Founded in 2003, Trio provides comprehensive clinical, functional outsourcing and resourcing services across a wide-range of therapeutic areas in phase I-IV clinical research. Trio’s extensive customer base includes a majority of the world’s top pharmaceutical and biotech companies.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
